A Phase 1 interventional study of GS-248 and Placebo in Healthy, sponsored by Gesynta Pharma AB. Completed at 1 site in Sweden. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-11.
Sponsored by Gesynta Pharma AB · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a First in Human (FIH), double-blinded, parallel-group, randomised, placebo-controlled study designed to evaluate the safety, tolerability, PK and PD of single and multiple ascending oral doses of GS-248 in healthy subjects.
Part I (SAD); In the SAD part of the study, single oral doses of GS-248 will be administered in 6 sequential cohorts, each consisting of 8 subjects randomised to receive either GS 248 or placebo in a 3:1 ratio. The first 2 subjects in each cohort will be dosed in a sentinel fashion; 1 subject will receive GS-248 and the other will receive placebo as randomised. The subjects will be carefully monitored by clinical staff during and after dosing. Vital signs, safety laboratory and ECG will be checked at regular intervals.
Part II (MAD); The MAD part of the study will explore multiple ascending dosing of GS-248 administered for 10 days. The proposed starting dose is 25 mg/day. However, the starting dose as well as subsequent dose levels may be adjusted based on safety and PK evaluation in previous cohorts. GS-248 will be administered in 4 sequential cohorts, each of 8 subjects randomised to receive either GS 248 or placebo in a 3:1 ratio. The subjects will be carefully monitored by clinical staff during and after dosing. Vital signs, safety laboratory and ECG will be checked at regular intervals.
Gesynta Pharma AB is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women of child bearing potential must practice abstinence or must agree to use a highly effective method of with a failure rate of \< 1% to prevent pregnancy from at least 4 weeks prior to dose to 4 weeks after last dose. Their male partner must agree to use a condom during the same time frame. Women of non- are defined as pre-menopausal females who are sterilised or defined as 12 months of amenorrhea.
Male subjects must be willing to use condom or be vasectomised or practice sexual abstinence. Their female partner of child-bearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy (see above).
Exclusion Criteria:
After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part I (SAD): Single doses of 1 mg, 5 mg, 25 mg, 75 mg, 225 mg and 450 mg (planned doses) Part II (MAD): Multiple ascending doses for 10 days in four cohorts with planned doses of 25 mg, 75 mg, 225 mg and 450 mg. The doses will be finally selected based on results from Part I.
Drug: GS-248
Matching placebo oral solution
Drug: Placebo
GS-248 oral solution
Placebo oral solution with the same composition to match active drug
Number of Treatment Related Adverse Events
AEs were assessed as 'unlikely', 'possibly' or 'probably' related to the IMP. 'Possibly' and 'probably' were categorized as treatment related.
Time frame: AEs were collected from the start of IMP administration until the end-of-study visit of each part, an average of 10 days in Part 1 (SAD) and 20 days in Part 2 (MAD).
Clinically Significant Changes in ECG
Single 12-lead ECG was recorded in supine position after 10 minutes of rest using an ECG machine. Heart rate and PQ/PR, QRS, QT and QTcF intervals were recorded. Ambulatory ECG telemetry was used for cardiac surveillance up to 24 h after IMP administration in the SAD part of the study.
Time frame: 12-lead ECG was measured at pre-defined timepoints from the screening visit until the end-of-study visit, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).
Clinically Significant Changes in Vital Signs
Systolic and diastolic blood pressure and pulse were measured in supine position after 10 minutes of rest. Body temperature was measured orally using a digital thermometer.
Time frame: Vital signs was checked at pre-defined timepoints from the screening visit until the end-of-study visit, an average of 10 days in Part 1 (SAD) and 20 days in Part 2 (MAD).
Clinically Significant Changes in Safety Laboratory Parameters
Blood samples for analysis of clinical chemistry, haematology and coagulation parameters.
Time frame: Blood samples were collected at pre-defined timepoints from the screening visit until the end-of-study visit, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).
Clinically Significant Changes in Physical Examination
A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities.
Time frame: Physical examination was performed at pre-defined timepoints from the screening visit until the end-of- study visit, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).
Cmax:
Maximum plasma concentration.
Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose; MAD Day 1-3 (first dose) and Day 10-12 (last dose): pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Tmax:
Time to Cmax.
Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose; MAD: Day 1-3 (first dose) Day 10-12 (last dose): pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
T½:
Terminal elimination half-life
Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
AUC0-t:
Area under the concentration time curve from the time of dosing to the time of the last observation.
Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
AUC 0-inf
Area under the curve from time 0 to infinity.
Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose
AUCss
Area under the plasma concentration curve during a dosing interval at steady state.
Time frame: MAD: Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Clearance (CL)/F:
Apparent total body clearance following extravascular administration.
Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Vz/F:
Apparent volume of distribution following extravascular administration
Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Accumulation Ratio AUC 0-ss
Time frame: MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
mPGES-1 Activity
Ex vivo determination of mPGES-1 activity in a Whole Blood Assay (WBA) measured as percent change from baseline of Prostaglandin E2 (PGE2) levels after lipopolysaccharide (LPS) stimulation.
Time frame: At 24h after first dose Day 1 and at 24 hours after last dose Day 10.
Subjects were recruited from CTC's database of healthy volunteers and from advertising in media (including social media). Screening visits were performed at CTC research clinic. Part I (SAD): Recruitment period started 19JUN2019 and lasted until 15OCT2019. Part II (MAD): Recruitment period started in August 2019 (when first SAD cohorts had been completed) and lasted until 25NOV2019.
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AEs were assessed as 'unlikely', 'possibly' or 'probably' related to the IMP. 'Possibly' and 'probably' were categorized as treatment related.
| Number of events | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | Placebo (SAD) | GS-248 20 mg (MAD) | GS-248 60 mg (MAD) | GS-248 180 mg (MAD) | Placebo (MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Treatment Related Adverse Events | 3 | 4 | 0 | 3 | 2 | 1 | 4 | 1 | 12 | 9 | 0 |
Single 12-lead ECG was recorded in supine position after 10 minutes of rest using an ECG machine. Heart rate and PQ/PR, QRS, QT and QTcF intervals were recorded. Ambulatory ECG telemetry was used for cardiac surveillance up to 24 h after IMP administration in the SAD part of the study.
| Number of abnormal CS events | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | Placebo (SAD) | GS-248 20 mg (MAD) | GS-248 60 mg (MAD) | GS-248 180 mg (MAD) | Placebo (MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinically Significant Changes in ECG | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Systolic and diastolic blood pressure and pulse were measured in supine position after 10 minutes of rest. Body temperature was measured orally using a digital thermometer.
| Number of abnormal CS events | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | Placebo (SAD) | Total (SAD) | GS-248 20 mg (MAD) | GS-248 60 mg (MAD) | GS-248 180 mg (MAD) | Placebo (MAD) | Total (MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinically Significant Changes in Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples for analysis of clinical chemistry, haematology and coagulation parameters.
| Participants | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | Placebo (SAD) | Total (SAD) | GS-248 20 mg (MAD) | GS-248 60 mg (MAD) | GS-248 180 mg (MAD) | Placebo (MAD) | Total (MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinically Significant Changes in Safety Laboratory Parameters | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 3 |
A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities.
| Participants | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | Placebo (SAD) | Total (SAD) | GS-248 20 mg (MAD) | GS-248 60 mg (MAD) | GS-248 180 mg (MAD) | Placebo (MAD) | Total (MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinically Significant Changes in Physical Examination | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
Maximum plasma concentration.
| nmol/L | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | GS-248 20 mg (MAD First Dose) | GS-248 60 mg (MAD First Dose) | GS-248 180 mg MAD (First Dose) | GS-248 20 mg (MAD Last Dose) | GS-248 60 mg (MAD Last Dose) | GS-248 180 mg MAD (Last Dose) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax: | 1.247 ± 0.9537 | 8.975 ± 4.971 | 11.82 ± 4.365 | 145.3 ± 69.75 | 263.3 ± 65.07 | 818.3 ± 783.3 | 41.47 ± 18.45 | 231.8 ± 187.3 | 478.5 ± 310.0 | 43.93 ± 30.10 | 176.5 ± 83.04 | 903.0 ± 590.6 |
Time to Cmax.
| hours | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | GS-248 20 mg (MAD First Dose) | GS-248 60 mg (MAD First Dose) | GS-248 180 mg (MAD First Dose) | GS-248 20 mg (MAD Last Dose) | GS-248 60 mg (MAD Last Dose) | GS-248 180 mg (MAD Last Dose) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax: | 1.500 (1.00 to 1.50) | 2.500 (1.50 to 3.00) | 1.000 (1.00 to 2.00) | 1.000 (0.500 to 1.50) | 1.000 (0.500 to 1.50) | 1.500 (1.00 to 2.00) | 1.000 (0.500 to 2.00) | 1.000 (0.500 to 1.00) | 1.108 (0.517 to 2.00) | 2.000 (1.00 to 2.00) | 1.000 (0.500 to 2.02) | 2.000 (1.02 to 2.05) |
Terminal elimination half-life
| hours | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | GS-248 20 mg (MAD First Dose) | GS-248 60 mg (MAD First Dose) | GS-248 180 mg (MAD First Dose) | GS-248 20 mg (MAD Last Dose) | GS-248 60 mg (MAD Last Dose) | GS-248 180 mg (MAD Last Dose) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T½: | 4.539 ± 2.435 | 1.089 ± 0.1879 | 1.660 ± 0.3684 | 9.220 ± 6.697 | 9.513 ± 3.683 | 11.14 ± 1.630 | 3.469 ± 2.073 | 6.705 ± 3.120 | 11.86 ± 10.76 | 6.504 ± 3.980 | 18.00 ± 8.750 | 15.01 ± 5.225 |
Area under the concentration time curve from the time of dosing to the time of the last observation.
| h*nmol/L | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | GS-248 20 mg (MAD First Dose) | GS-248 60 mg (MAD First Dose) | GS-248 180 mg (MAD First Dose) | GS-248 20 mg (MAD Last Dose) | GS-248 60 mg (MAD Last Dose) | GS-248 180 mg (MAD Last Dose) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC0-t: | 2.437 ± 1.846 | 30.57 ± 22.88 | 39.08 ± 13.40 | 478.6 ± 285.3 | 879.8 ± 380.0 | 2667 ± 2850 | 180.1 ± 75.75 | 655.8 ± 473.7 | 1735 ± 1164 | 211.0 ± 115.5 | 650.5 ± 267.2 | 4798 ± 3702 |
Area under the curve from time 0 to infinity.
| h*nmol/L | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) |
|---|---|---|---|---|---|---|
| AUC 0-inf | 8.542 ± 0.8438 | 40.22 ± 24.62 | 41.77 ± 13.80 | 489.3 ± 282.3 | 894.7 ± 380.8 | 2713 ± 2906 |
Area under the plasma concentration curve during a dosing interval at steady state.
| h*nmol/L | GS-248 20 mg (MAD) | GS-248 60 mg (MAD) | GS-248 180 mg (MAD) |
|---|---|---|---|
| AUCss | 205.9 ± 103.4 | 604.6 ± 233.1 | 4046 ± 2823 |
Apparent total body clearance following extravascular administration.
| L/h | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | GS-248 20 mg (MAD First Dose) | GS-248 60 mg (MAD First Dose) | GS-248 180 mg (MAD First Dose) | GS-248 20 mg (MAD Last Dose) | GS-248 60 mg (MAD Last Dose) | GS-248 180 mg (MAD Last Dose) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clearance (CL)/F: | 173.7 ± 17.51 | 228.2 ± 102.7 | 304.8 ± 83.80 | 161.4 ± 92.39 | 184.8 ± 58.74 | 318.2 ± 223.4 | 187.0 ± 79.05 | 190.2 ± 109.1 | 181.2 ± 101.4 | 175.4 ± 81.81 | 166.2 ± 63.62 | 97.59 ± 74.02 |
Apparent volume of distribution following extravascular administration
| L | GS-248 1 mg (SAD) | GS-248 5 mg (SAD) | GS-248 8 mg (SAD) | GS-248 40 mg (SAD) | GS-248 100 mg (SAD) | GS-248 300 mg (SAD) | GS-248 20 mg (MAD) | GS-248 60 mg (MAD) | GS-248 180 mg (MAD) |
|---|---|---|---|---|---|---|---|---|---|
| Vz/F: | 1097 ± 516.4 | 341.9 ± 120.5 | 719.7 ± 192.1 | 2117 ± 2445 | 2378 ± 918.8 | 4856 ± 3394 | 1354 ± 392.3 | 3945 ± 1685 | 2157 ± 2139 |
| ratio | GS-248 20 mg (MAD) | GS-248 60 mg (MAD) | GS-248 180 mg (MAD) |
|---|---|---|---|
| Accumulation Ratio AUC 0-ss | 1.148 ± 0.3148 | 1.171 ± 0.5541 | 2.390 ± 1.135 |
Ex vivo determination of mPGES-1 activity in a Whole Blood Assay (WBA) measured as percent change from baseline of Prostaglandin E2 (PGE2) levels after lipopolysaccharide (LPS) stimulation.
| Relative change from baseline (%) | Day 1 (SAD): 5 mg | Day 1 (SAD): 40 mg | Day 1 (SAD): 100 mg | Day 1 (SAD): 300 mg | Day 1 (MAD): 20 mg | Day 1 (MAD): 60 mg | Day 1 (MAD): 180 mg | Day 1 (SAD and MAD): Placebo | Day 10 (MAD): 20 mg | Day 10 (MAD): 60 mg | Day 10 (MAD): 180 mg | Day 10 (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mPGES-1 Activity | 7.2 ± 98.8 | -97.1 ± 12.1 | -108.3 ± 11.5 | -105.2 ± 11.6 | -65.9 ± 20.2 | -94.9 ± 9.3 | -104.3 ± 6.8 | 9.8 ± 59.6 | -86.9 ± 26.8 | -104.3 ± 13.9 | -109.8 ± 7.8 | 18.6 ± 57.7 |
Collected over AEs (including serious AEs [SAEs]) were collected from the start of IMP application until the end-of- study visit of each part, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part I (SAD): 1 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part I (SAD): 5 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part I (SAD): 8 mg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part I (SAD): 40 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part I (SAD): 100 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part I (SAD): 300 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part I (SAD): Placebo | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Part II (MAD): 20 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part II (MAD): 60 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part II (MAD): 180 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part II (MAD): Placebo | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/6 | 3/6 | 0/6 | 0/6 | 1/6 | 2/6 | 2/12 | 1/6 | 2/6 | 1/6 | 1/6 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/6 | 2/6 | 2/6 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 2/6 | 1/6 | 0/6 |
| FlatulenceGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 1/6 | 2/6 | 1/6 | 0/6 |
| RashSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/6 | 2/6 | 1/6 |
| ConstipationGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 |
| Lip dryGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 |
| NauseaGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/12 | 0/6 | 1/6 | 0/6 | 0/6 |
| VomitingGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 |
| Age, Continuous(years) | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part I (SAD) | 40.7 ± 21.5 | 33.7 ± 9.8 | 36.8 ± 21.4 | 41.8 ± 15.9 | 50.7 ± 10.8 | 33.7 ± 13.0 | 32.4 ± 14.1 | — | — | — | — | 37.8 ± 15.8 |
| Part II (MAD) | — | — | — | — | — | — | — | 56.7 ± 12.2 | 58.2 ± 11.0 | 58.2 ± 12.2 | 59.0 ± 13.9 | 58.0 ± 11.6 |
| Sex: Female, Male(Participants) | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part I (SAD) — Female | 2 | 3 | 1 | 3 | 4 | 4 | 3 | — | — | — | — | 20 |
| Part I (SAD) — Male | 4 | 3 | 5 | 3 | 2 | 2 | 9 | — | — | — | — | 28 |
| Part II (MAD) — Female | — | — | — | — | — | — | — | 4 | 4 | 4 | 3 | 15 |
| Part II (MAD) — Male | — | — | — | — | — | — | — | 2 | 2 | 2 | 3 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part I (SAD) — Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Part I (SAD) — Not Hispanic or Latino | 6 | 6 | 6 | 5 | 6 | 6 | 12 | 0 | 0 | 0 | 0 | 47 |
| Part I (SAD) — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part II (MAD) — Hispanic or Latino | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Part II (MAD) — Not Hispanic or Latino | — | — | — | — | — | — | — | 6 | 6 | 6 | 6 | 24 |
| Part II (MAD) — Unknown or Not Reported | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| part I (MAD) — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| part I (MAD) — Asian | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 4 |
| part I (MAD) — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| part I (MAD) — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| part I (MAD) — White | 4 | 5 | 6 | 6 | 6 | 6 | 11 | 0 | 0 | 0 | 0 | 44 |
| part I (MAD) — More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| part I (MAD) — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part II (MAD) — American Indian or Alaska Native | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Part II (MAD) — Asian | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Part II (MAD) — Native Hawaiian or Other Pacific Islander | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Part II (MAD) — Black or African American | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Part II (MAD) — White | — | — | — | — | — | — | — | 6 | 6 | 6 | 6 | 24 |
| Part II (MAD) — More than one race | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Part II (MAD) — Unknown or Not Reported | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sweden | 6 | 6 | 6 | 6 | 6 | 6 | 12 | 6 | 6 | 6 | 6 | 72 |
| BMI(kg/m^2) | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part I (SAD) | 22.3 ± 2.6 | 25.2 ± 3.9 | 25.2 ± 3.4 | 25.7 ± 3.4 | 26.0 ± 2.2 | 22.0 ± 2.0 | 24.0 ± 3.0 | — | — | — | — | 24.4 ± 3.2 |
| Part II (MAD) | — | — | — | — | — | — | — | 26.0 ± 1.3 | 23.5 ± 2.7 | 24.3 ± 1.6 | 25.8 ± 3.5 | 24.9 ± 2.5 |
| Height(cm) | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part I (SAD) | 171.3 ± 13.6 | 169.0 ± 11.0 | 178.0 ± 4.4 | 176.7 ± 13.9 | 176.2 ± 9.6 | 173.3 ± 10.3 | 175.7 ± 10.4 | — | — | — | — | 174.1 ± 10.6 |
| Part II (MAD) | — | — | — | — | — | — | — | 171.0 ± 11.9 | 171.7 ± 8.0 | 172.2 ± 6.8 | 176.0 ± 12.7 | 172.7 ± 9.7 |
| Weight(kg) | Part I (SAD): 1 mg | Part I (SAD): 5 mg | Part I (SAD): 8 mg | Part I (SAD): 40 mg | Part I (SAD): 100 mg | Part I (SAD): 300 mg | Part I (SAD): Placebo | Part II (MAD): 20 mg | Part II (MAD): 60 mg | Part II (MAD): 180 mg | Part II (MAD): Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part I (SAD) | 65.7 ± 13.4 | 72.5 ± 16.9 | 79.8 ± 13.3 | 81.0 ± 18.0 | 81.0 ± 11.0 | 66.3 ± 8.2 | 74.7 ± 13.8 | — | — | — | — | 74.4 ± 14.5 |
| Part II (MAD) | — | — | — | — | — | — | — | 76.2 ± 9.0 | 69.8 ± 11.9 | 72.3 ± 5.5 | 81.0 ± 17.2 | 74.8 ± 11.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Dec 2019, 5 months.
Results were first posted in Sep 2023, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vipoglanstat
Gesynta Pharma AB